Abstract:CAR NK‐92 is activated through specific recognition of PSMA on prostate cancer cells. Expression of PD‐L1 on activated CAR NK‐92 is upregulated via CAR‐triggered PI3K/AKT/mTOR pathway. Expression of PD‐L1 on cancer cells is upregulated via IFN‐γ‐mediated JAK‐STAT pathway. Atezolizumab potentiates CAR NK‐92 cytotoxicity by directly acting on PD‐L1 on CAR NK‐92 and unleashes CD8+ T cell via blocking PD‐L1/PD‐1 axis. Background The chimeric antigen receptor NK‐92 (CAR NK‐92) cell targeting the prostate‐specific membrane antigen (PSMA) has shown antitumour effects in castration‐resistant prostate cancer (CRPC). However, the expression changes of programmed death ligand 1 (PD‐L1) and its mechanisms on CAR NK‐92 and CRPC cells and the effect of the anti‐PD‐L1 monoclonal antibody (mAb) on PD‐L1 expressed on CAR NK‐92 cells remain unknown. Methods Human dendritic cells and CD8+ T cells were acquired from blood samples of healthy donors and cocultured with C4‐2 cells. Changes in PD‐L1 expression were detected by flow cytometry. Differential gene expressions were investigated by RNA sequence analysis, while the regulation of PD‐L1 molecular signaling was explored using western blotting. In vitro cytotoxicity was evaluated using the Cell Counting Kit‐8 assay and the bioluminescent intensity (BLI) of green fluorescent protein‐labelled C4‐2 cells. CRPC growth in vivo was monitored using callipers and BLI in male NOD/SCID mice subcutaneously injected with C4‐2 cells and treated intravenously with anti‐PD‐L1/PD‐1 mAb, CAR NK‐92 or cocultured CD8+ T cells. Results Significantly upregulated expression of PD‐L1k was observed in cocultured C4‐2 and CAR NK‐92 cells. In addition, upregulation of PD‐L1 expression was dependent on interferon‐γ in C4‐2 cells, while it was dependent on direct cell‐to‐cell interaction via the NK group 2 member D/ phosphatidylinositol 3‐kinase/AKT pathway in CAR NK‐92 cells. The anti‐PD‐L1 mAb directly acted on PD‐L1 expressed on CAR NK‐92 cells and augmented the cytotoxicity of CAR NK‐92 cells against C4‐2 and CRPC cells from one patient in vitro. Anti‐PD‐L1 mAb significantly enhanced the antitumour effect of CAR NK‐92 cells against CRPC cells in vivo when compared to treatment with CAR NK‐92 cells or combined with anti‐PD‐1 mAb in the absence or presence of cocultured CD8+ T cells. Conclusion Combined treatment with CAR NK‐92 and anti‐PD‐L1 mAb improved the antitumour efficacy against CRPC, which is of extraordinary translational value in the clinical treatment of CRPC.

Antitumor Effects of Ad-PSMA-Pulsed Dendritic Cells Cocultured with Autologous Cytokine-Induced Killer Cells on Prostate Cancer in Vivo

Dendritic Cells Transduced with a PSMA-encoding Adenovirus and Cocultured with Autologous Cytokine-Induced Lymphocytes Induce a Specific and Strong Immune Response Against Prostate Cancer Cells.

Immune Effect of Co-Culture of Dendritic Cells and Cytokine-Induced Killer Cells on Prostate Cancer Cells

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

Dendritic Cells Serve As a "trojan Horse" for Oncolytic Adenovirus Delivery in the Treatment of Mouse Prostate Cancer.

The Immunotherapeutic Effect of Dendritic Cells Vaccine Modified with IFN-γ Inducible Protein-10 Gene and Tumor Cell Lysate on Mice with Prostate Cancer

Enhanced antitumor effects by the coculture of allotumor RNA-pulsed dendritic cells with autologous cytokine-induced killer cells on hormone-refractory prostate cancer.

Anti-tumor Response of Dendritic Cells after Pulsed with Whole Tumor Cell Lysates of Prostate Cancer Cell Line

Dendritic Cell Immunotherapy Induces Anti-Tumor Effect in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma.

The anti-tumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo

Intralesional Chemotherapy for Prostate Cancer: In Vivo Proof of Principle

The Antitumor Effects Of Cik Cells Combined With Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line Spc-A1/Dtx In Vitro And In Vivo

TGF-β insensitive dendritic cells: an efficient vaccine for murine prostate cancer

Experiment Study of Allotumor RNA-pulsed DCs Cocultured with Autologous CIKs Regulating and Controlling Akt/NF-κB Cell-Survival Signaling Pathway

Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancer

The Antitumor Effects of CIK Cells Combined with Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line SPC-A1/DTX in Vitro and in Vivo.

Allogeneic Expanded Human Peripheral NK Cells Control Prostate Cancer Growth in a Preclinical Mouse Model of Castration-Resistant Prostate Cancer

PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway

Research of dendritic cells pulsed with PSA peptide inducing specific CTL in vitro

Prophylactic Dendritic Cell Vaccination Controls Pancreatic Cancer Growth in a Mouse Model.